Females of childbearing potential who are pregnant, lactating, or who have not adhered to an adequate contraception method from at least 30 days prior to study entry and who do not plan to do so for at least 1 month post last supplementation,Patients that are doing hormonal replacement therapy, severe COVID-19 pneumonia according to CDC criteria associated with CT Severe Illness Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple organ, positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies, known or suspected alcohol or drug abuse within the past 6 months prior to screening,participation in another experimental protocol and/or receipt of any investigational products within the past 3 months prior to screening,treatment with immunosuppressive cytotoxic therapies (e.g., chemotherapy drugs or radiation) in the past 6 months prior to screening,patients unable to sign the inform consent to participate into the study, History of any other acute or uncontrolled chronic illness (including, hypertension, cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic or renal disorders) that is not on medication regimen for at least the past 6 months, or use of medication or supplements that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety and tolerability of the study drug such as ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs)

Females of childbearing potential who are pregnant, lactating, or who have not adhered to an adequate contraception method from at least 30 days prior to study entry and who do not plan to do so for at least 1 month post last supplementation,Patients that are doing hormonal replacement therapy, severe COVID-19 pneumonia according to CDC criteria associated with CT Severe Illness Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple organ, positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies, known or suspected alcohol or drug abuse within the past 6 months prior to screening,participation in another experimental protocol and/or receipt of any investigational products within the past 3 months prior to screening,treatment with immunosuppressive cytotoxic therapies (e.g., chemotherapy drugs or radiation) in the past 6 months prior to screening,patients unable to sign the inform consent to participate into the study, History of any other acute or uncontrolled chronic illness (including, hypertension, cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic or renal disorders) that is not on medication regimen for at least the past 6 months, or use of medication or supplements that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety and tolerability of the study drug such as ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs)